Tranzyme, a biotechnology company, which recently relocated its headquarters to RTP from Alabama, has won a $500,000 grant from the Institute for the Study of Aging.
The money is part of the group’s commitment to fight Alzheimer’s disease.
Tranzyme is focused on developing innovative theories for treatment of neurosensory diseases.
“Our support of Tranzyme is consistent with ISOA’s mission to provide early stage biotechnology companies with funding for specific research programs related to drug discovery for Alzheimer’s disease,” said Howard Fillit, the institute’s executive director, in a statement. “We are proud to support Tranzyme in their development of new animal models for Alzheimer’s disease that will be key to the pre-clinical discovery and development of new drugs.”
Tranzyme plans to use a transgenic rat model as well as non-transgenic mouse models in its Alzheimer’s research.
The ISOA is a biomedical philanthropy venture with a mission of spurring research, discovery and development of new drugs and therapies to prevent and to treat cognitive aging and Alzheimer’s disease.